Reported about 10 hours ago
AbbVie announced its acquisition of Capstan Therapeutics, a developer of CAR-T cell therapies, for up to $2.1 billion as part of its strategy to enhance its product pipeline for treating autoimmune diseases. This purchase follows AbbVie's significant investment in acquisitions after the loss of patent protection for its leading rheumatoid arthritis drug, Humira. The deal is expected to strengthen AbbVie's position in the competitive landscape of inflammatory disease treatments.
Source: YAHOO